Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings)
- PMID: 1185162
- DOI: 10.1007/BF01663632
Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings)
Abstract
1. A Dopa-medication leads sometimes in Parkinsonian patients to a psychosis. 2. The diminished capacity of striatal dopaminergic neurons to store DA leads to a storage of DA in serotoninergic or noradrenergic neurons. 3. Extrastriatal noradrenergic and/or serotoninergic neurons are involved. 4. Dopaminergic receptors of the striatium are not involved because of a lack of kinetic response after L-Dopa application in Parkinsonian patients with akinetic crises. 5. Extrastriatal dopaminergic receptors of DA as "false transmitter" at serotoninergic receptors seem to be responsible for the production of psychotic symptoms, whereas noradrenaline is not responsible. Psychotic symptoms can be imagined to be triggered by a contact of a transmitter to a nonspecific receptor.
Similar articles
-
Peculiarities of L: -DOPA treatment of Parkinson's disease.Amino Acids. 2005 Mar;28(2):157-64. doi: 10.1007/s00726-005-0162-4. Epub 2005 Mar 9. Amino Acids. 2005. PMID: 15750845 Review.
-
Nucleus ruber and L-dopa psychosis: biochemical post-mortem findings.J Neural Transm. 1974;35(2):93-116. doi: 10.1007/BF01250738. J Neural Transm. 1974. PMID: 4844103 No abstract available.
-
Pathophysiology of L-dopa-induced abnormal involuntary movements.Psychopharmacology Suppl. 1985;2:145-59. doi: 10.1007/978-3-642-70140-5_19. Psychopharmacology Suppl. 1985. PMID: 2987904
-
Dopaminergic supersensitivity in parkinsonism.Adv Neurol. 1975;9:121-9. Adv Neurol. 1975. PMID: 1146650 No abstract available.
-
Parkinson's disease: drug-induced psychiatric states.Adv Neurol. 1995;65:115-38. Adv Neurol. 1995. PMID: 7872135 Review.
Cited by
-
Psychotic symptoms in Parkinson's disease. From description to etiology.J Neurol. 2005 Jul;252(7):753-64. doi: 10.1007/s00415-005-0918-5. J Neurol. 2005. PMID: 15999234 Review.
-
Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson's disease.J Neural Transm (Vienna). 1996;103(10):1195-204. doi: 10.1007/BF01271204. J Neural Transm (Vienna). 1996. PMID: 9013406
-
Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.Drugs Aging. 1997 May;10(5):367-83. doi: 10.2165/00002512-199710050-00005. Drugs Aging. 1997. PMID: 9143857 Review.
-
Non-motor features of Parkinson disease.Nat Rev Neurosci. 2017 Jul;18(7):435-450. doi: 10.1038/nrn.2017.62. Epub 2017 Jun 8. Nat Rev Neurosci. 2017. PMID: 28592904 Review.
-
Psychosis in Parkinson's disease.Postgrad Med J. 2005 Oct;81(960):644-6. doi: 10.1136/pgmj.2004.032029. Postgrad Med J. 2005. PMID: 16210460 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources